Dechra Pharmaceuticals (DCHPF) Stock Price, News & Analysis

Company Overview

Dechra Pharmaceuticals is a global specialty pharmaceutical company focused on the development, manufacture and marketing of veterinary products for both companion animals and livestock. Headquartered in Northwich, Cheshire, UK, the company’s portfolio encompasses a wide range of therapeutic areas, including endocrinology, dermatology, analgesia, anti-infectives and anaesthesia. Dechra’s integrated model combines in-house research and development with state-of-the-art manufacturing facilities to deliver targeted solutions that improve animal health and welfare.

The company’s product range includes branded pharmaceuticals, generic medications and complementary feed supplements. Key offerings span hormonal treatments for endocrine disorders, topical and systemic therapies for skin conditions and pain management products designed for surgical and chronic use. Dechra also provides veterinary dermatology lines addressing allergic and inflammatory skin diseases, as well as anti-infectives formulated to combat bacterial and fungal infections in a variety of species.

Established in the late 1990s as a specialist animal-health spin-out, Dechra Pharmaceuticals has grown organically and through strategic acquisitions to become a leading player in the veterinary pharmaceutical market. Over the past two decades, the company has expanded its research capabilities and broadened its product pipeline by acquiring niche businesses that complement its core therapeutic focus. This disciplined acquisition strategy has allowed Dechra to enhance market share in key sectors and rapidly introduce new products to market.

Dechra serves customers in Europe, North America, Australia and select emerging markets, supported by a network of sales and distribution offices in major regions. The company is led by a seasoned executive team with extensive experience in veterinary medicine, regulatory affairs and pharmaceutical manufacturing. Under this leadership, Dechha continues to pursue innovation through targeted R&D investments and strategic partnerships, aiming to address unmet needs in animal health around the world.

Key Stats

• Today's Range: $46.90 to $46.90
• 50-Day Range: $46.90 to $46.90
• 52-Week Range: $30.00 to $47.40
• Volume: N/A
• Average Volume: 1,687 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DCHPF Stock Analysis - Frequently Asked Questions

How have DCHPF shares performed this year?

Dechra Pharmaceuticals' stock was trading at $46.90 at the start of the year. Since then, DCHPF shares have increased by 0.0% and is now trading at $46.90.

How do I buy shares of Dechra Pharmaceuticals?

Shares of DCHPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:DCHPF
• CIK: N/A
• Web: dechra.com
• Phone: 441606814730
• Fax: N/A
• Employees: 2,457
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A